Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants

Nicolas Wentzensen, Mark Schiffman, Terence Dunn, Rosemary E. Zuna, Michael A. Gold, Richard A. Allen, Roy Zhang, Mark E. Sherman, Sholom Wacholder, Joan Walker, Sophia S. Wang

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Determining the causal attribution of human papillomavirus (HPV) genotypes to cervical disease is important to estimate the effect of HPV vaccination and to establish a type spectrum for HPV-based screening. We analyzed the prevalence of HPV infections and their attribution to cervical disease in a population of 1,670 women referred to colposcopy for abnormal cytology at the University of Oklahoma. HPV genotyping was performed from cytology specimens using the Linear Array assay that detects 37 HPV genotypes. We used different methods of type attribution to revised cervical disease categories. We found very high prevalence of multiple HPV infections with up to 14 genotypes detected in single specimens. In all disease categories except for cancers, there was a significant trend of having more infections at a younger age. We did not see type interactions in multiple genotype infections. HPV16 was the most frequent genotype at all disease categories. Based on different attribution strategies, the attribution of vaccine genotypes (6, 11, 16, 18) ranged from 50.5 to 67.3% in cancers (n = 107), from 25.6 to 74.8% in CIN3 (n = 305), from 15.2 to 52.2% in CIN2 (n = 427), and from 6.6 to 26.0% in <CIN2 (n = 708). In the HSIL cytology group (n = 651), attribution ranged from 26.1 to 64.7%. The attribution of vaccine types to HSIL was substantially higher compared to the lower cytology categories. The potential range of HPV genotype attribution is wide at the disease categories <CIN2 to CIN3. Genotyping from cervical lesions and analyzing viral oncogene expression can improve estimates of HPV genotype attribution.

Original languageEnglish (US)
Pages (from-to)2151-2158
Number of pages8
JournalInternational Journal of Cancer
Volume125
Issue number9
DOIs
StatePublished - Nov 1 2009

Fingerprint

Papillomavirus Infections
Uterine Cervical Neoplasms
Genotype
Cell Biology
Vaccines
Colposcopy
Infection
Oncogenes
Neoplasms
Vaccination

Keywords

  • Cervical cancer
  • Epidemiology
  • HPV
  • Molecular
  • SUCCEED

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. / Wentzensen, Nicolas; Schiffman, Mark; Dunn, Terence; Zuna, Rosemary E.; Gold, Michael A.; Allen, Richard A.; Zhang, Roy; Sherman, Mark E.; Wacholder, Sholom; Walker, Joan; Wang, Sophia S.

In: International Journal of Cancer, Vol. 125, No. 9, 01.11.2009, p. 2151-2158.

Research output: Contribution to journalArticle

Wentzensen, N, Schiffman, M, Dunn, T, Zuna, RE, Gold, MA, Allen, RA, Zhang, R, Sherman, ME, Wacholder, S, Walker, J & Wang, SS 2009, 'Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants', International Journal of Cancer, vol. 125, no. 9, pp. 2151-2158. https://doi.org/10.1002/ijc.24528
Wentzensen, Nicolas ; Schiffman, Mark ; Dunn, Terence ; Zuna, Rosemary E. ; Gold, Michael A. ; Allen, Richard A. ; Zhang, Roy ; Sherman, Mark E. ; Wacholder, Sholom ; Walker, Joan ; Wang, Sophia S. / Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. In: International Journal of Cancer. 2009 ; Vol. 125, No. 9. pp. 2151-2158.
@article{377ee8e45f8e4c6085b9b8c93e7c0f45,
title = "Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants",
abstract = "Determining the causal attribution of human papillomavirus (HPV) genotypes to cervical disease is important to estimate the effect of HPV vaccination and to establish a type spectrum for HPV-based screening. We analyzed the prevalence of HPV infections and their attribution to cervical disease in a population of 1,670 women referred to colposcopy for abnormal cytology at the University of Oklahoma. HPV genotyping was performed from cytology specimens using the Linear Array assay that detects 37 HPV genotypes. We used different methods of type attribution to revised cervical disease categories. We found very high prevalence of multiple HPV infections with up to 14 genotypes detected in single specimens. In all disease categories except for cancers, there was a significant trend of having more infections at a younger age. We did not see type interactions in multiple genotype infections. HPV16 was the most frequent genotype at all disease categories. Based on different attribution strategies, the attribution of vaccine genotypes (6, 11, 16, 18) ranged from 50.5 to 67.3{\%} in cancers (n = 107), from 25.6 to 74.8{\%} in CIN3 (n = 305), from 15.2 to 52.2{\%} in CIN2 (n = 427), and from 6.6 to 26.0{\%} in <CIN2 (n = 708). In the HSIL cytology group (n = 651), attribution ranged from 26.1 to 64.7{\%}. The attribution of vaccine types to HSIL was substantially higher compared to the lower cytology categories. The potential range of HPV genotype attribution is wide at the disease categories <CIN2 to CIN3. Genotyping from cervical lesions and analyzing viral oncogene expression can improve estimates of HPV genotype attribution.",
keywords = "Cervical cancer, Epidemiology, HPV, Molecular, SUCCEED",
author = "Nicolas Wentzensen and Mark Schiffman and Terence Dunn and Zuna, {Rosemary E.} and Gold, {Michael A.} and Allen, {Richard A.} and Roy Zhang and Sherman, {Mark E.} and Sholom Wacholder and Joan Walker and Wang, {Sophia S.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1002/ijc.24528",
language = "English (US)",
volume = "125",
pages = "2151--2158",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants

AU - Wentzensen, Nicolas

AU - Schiffman, Mark

AU - Dunn, Terence

AU - Zuna, Rosemary E.

AU - Gold, Michael A.

AU - Allen, Richard A.

AU - Zhang, Roy

AU - Sherman, Mark E.

AU - Wacholder, Sholom

AU - Walker, Joan

AU - Wang, Sophia S.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Determining the causal attribution of human papillomavirus (HPV) genotypes to cervical disease is important to estimate the effect of HPV vaccination and to establish a type spectrum for HPV-based screening. We analyzed the prevalence of HPV infections and their attribution to cervical disease in a population of 1,670 women referred to colposcopy for abnormal cytology at the University of Oklahoma. HPV genotyping was performed from cytology specimens using the Linear Array assay that detects 37 HPV genotypes. We used different methods of type attribution to revised cervical disease categories. We found very high prevalence of multiple HPV infections with up to 14 genotypes detected in single specimens. In all disease categories except for cancers, there was a significant trend of having more infections at a younger age. We did not see type interactions in multiple genotype infections. HPV16 was the most frequent genotype at all disease categories. Based on different attribution strategies, the attribution of vaccine genotypes (6, 11, 16, 18) ranged from 50.5 to 67.3% in cancers (n = 107), from 25.6 to 74.8% in CIN3 (n = 305), from 15.2 to 52.2% in CIN2 (n = 427), and from 6.6 to 26.0% in <CIN2 (n = 708). In the HSIL cytology group (n = 651), attribution ranged from 26.1 to 64.7%. The attribution of vaccine types to HSIL was substantially higher compared to the lower cytology categories. The potential range of HPV genotype attribution is wide at the disease categories <CIN2 to CIN3. Genotyping from cervical lesions and analyzing viral oncogene expression can improve estimates of HPV genotype attribution.

AB - Determining the causal attribution of human papillomavirus (HPV) genotypes to cervical disease is important to estimate the effect of HPV vaccination and to establish a type spectrum for HPV-based screening. We analyzed the prevalence of HPV infections and their attribution to cervical disease in a population of 1,670 women referred to colposcopy for abnormal cytology at the University of Oklahoma. HPV genotyping was performed from cytology specimens using the Linear Array assay that detects 37 HPV genotypes. We used different methods of type attribution to revised cervical disease categories. We found very high prevalence of multiple HPV infections with up to 14 genotypes detected in single specimens. In all disease categories except for cancers, there was a significant trend of having more infections at a younger age. We did not see type interactions in multiple genotype infections. HPV16 was the most frequent genotype at all disease categories. Based on different attribution strategies, the attribution of vaccine genotypes (6, 11, 16, 18) ranged from 50.5 to 67.3% in cancers (n = 107), from 25.6 to 74.8% in CIN3 (n = 305), from 15.2 to 52.2% in CIN2 (n = 427), and from 6.6 to 26.0% in <CIN2 (n = 708). In the HSIL cytology group (n = 651), attribution ranged from 26.1 to 64.7%. The attribution of vaccine types to HSIL was substantially higher compared to the lower cytology categories. The potential range of HPV genotype attribution is wide at the disease categories <CIN2 to CIN3. Genotyping from cervical lesions and analyzing viral oncogene expression can improve estimates of HPV genotype attribution.

KW - Cervical cancer

KW - Epidemiology

KW - HPV

KW - Molecular

KW - SUCCEED

UR - http://www.scopus.com/inward/record.url?scp=70249150425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249150425&partnerID=8YFLogxK

U2 - 10.1002/ijc.24528

DO - 10.1002/ijc.24528

M3 - Article

VL - 125

SP - 2151

EP - 2158

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -